Inactive Instrument

Highlights Reata Pharmaceuticals, Inc.

Equities

RETA

US75615P1030

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Biogen Inc. acquired Reata Pharmaceuticals, Inc..	23-09-25	CI
Reata Pharmaceuticals Shareholders Approve Buyout by Biogen	23-09-21	MT
Sanofi Reportedly Second Bidder for Reata	23-08-16	CI
Sanofi Lost Reata Pharmaceuticals to Biogen, Regulatory Filing Shows	23-08-16	MT
Reata Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08	CI
Byotrol loss widens, Surface Transforms sales grow	23-07-31	AN
Biogen to Acquire Reata Pharmaceuticals in $7.3 Billion Deal	23-07-28	MT
Biogen to Acquire Reata Pharmaceuticals in $7.3 Billion Deal	23-07-28	MT
Biogen to Buy Reata Pharmaceuticals for $172.50/Share in Cash; Deal Completion Anticipated in Q4	23-07-28	MT
Biogen to buy Reata for $6.5 billion to bulk up rare disease portfolio	23-07-28	RE
Biogen Reportedly Considering Reata Acquisition, Reata Shares Rally Premarket	23-07-28	MT
Biogen considering takeover of biotech Reata - Bloomberg Law	23-07-28	RE
Chip Stocks Weigh on Exchange-Traded Funds, Equity Futures Pre-Bell Wednesday	23-06-28	MT
Reata Pharmaceuticals, Inc. Announces Approval of Prior Approval Supplement for SKYCLARYSÂ®? (Omaveloxolone) and Commercial Availability of SKYCLARYS for Patients with Friedreich's Ataxia	23-06-27	CI
Reata Pharmaceuticals Q1 Non-GAAP Loss Widens, Revenue Falls	23-05-10	MT
Reata Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
Earnings Flash (RETA) REATA PHARMACEUTICALS Posts Q1 Revenue $195,000, vs. Street Est of $160,000	23-05-10	MT
Reata Pharmaceuticals Says FDA Approves Treatment for Friedreich's Ataxia in Adults and Adolescents; Shares Surge Pre-Bell	23-03-01	MT
U.S. FDA approves Reata's rare genetic disorder drug	23-02-28	RE
U.S. FDA approves Reata's rare genetic disorder drug	23-02-28	RE

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Reata Pharmaceuticals, Inc.

Equities

RETA

US75615P1030

Highlights

Filters